Allergic and Immunologic Disorders
Curateq Biologics Private Limited funds clinical research in chronic spontaneous urticaria, with attention to patients who have an inadequate response to H1 antihistamines and require alternative biologic treatment options.
- Chronic spontaneous urticaria
- Anti-IgE therapy
- Biosimilar monoclonal antibodies
The sponsor’s work in this area reflects interest in immune-mediated skin disease and comparative biologic treatment options.
Bone Health and Metabolic Bone Disease
The sponsor supports research in post-menopausal osteoporosis, focusing on treatment options for preserving bone mineral density and controlling markers of bone turnover.
- Post-menopausal osteoporosis
- Bone mineral density
- Bone resorption markers
This area includes interest in RANKL-targeted therapy and comparative evaluation of biologic options for skeletal health.
Retinal and Ophthalmic Disease
Curateq Biologics Private Limited is also involved in research for wet age-related macular degeneration, a vision-threatening retinal disorder associated with abnormal angiogenesis and macular fluid accumulation.
- Wet age-related macular degeneration
- Retinal neovascular disease
- Anti-VEGF therapy
The sponsor’s ophthalmic interest centers on biologic treatment comparisons in diseases that affect central vision.
Biosimilar Therapeutics
Across its clinical portfolio, the sponsor shows a strong focus on biosimilar development and therapeutic equivalence assessment in immunology, endocrinology, and ophthalmology.
- Comparative biologic efficacy
- Pharmacodynamic endpoints
- Immunogenicity evaluation
Its funded studies span multiple therapeutic domains where biologic medicines are central to treatment.
